Literature DB >> 1680653

The disposition and metabolism of [14C]fluconazole in humans.

K W Brammer1, A J Coakley, S G Jezequel, M H Tarbit.   

Abstract

The disposition and metabolism of 14C-labeled fluconazole (100 microCi) was determined in three healthy male subjects after administration of a single oral capsule containing 50 mg of drug. Blood samples, total voided urine, and feces were collected at intervals after dosing for up to 12 days post-dose. Pharmacokinetic analysis of fluconazole concentrations showed a mean plasma half-life of 24.5 hr. Mean apparent plasma clearance and apparent volume of distribution were 0.23 ml/min/kg and 0.5 liter/kg, respectively. There was no evidence of any significant concentrations of metabolites circulating either in plasma or blood cells. Mean total radioactivity excreted in urine and feces represented 91.0 and 2.3%, respectively, of the administered dose. Mean excretion of unchanged drug in urine represented 80% of the administered dose; thus, only 11% was excreted in urine as metabolites. Only two metabolites were present in detectable quantities, a glucuronide conjugate of unchanged fluconazole and a fluconazole N-oxide, which accounted for 6.5 and 2.0% of urinary radioactivity, respectively. No metabolic cleavage products of fluconazole were detected.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1680653

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  17 in total

1.  Reply to Kara et al., "Might Confounding Factors Have an Effect on Suboptimal Dosing of Fluconazole in Critically Ill Patients?"

Authors:  E W Muilwijk; R J M Brüggemann
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

2.  Mechanisms of Acquired In Vivo and In Vitro Resistance to Voriconazole by Candida krusei following Exposure to Suboptimal Drug Concentration.

Authors:  Elisabete Ricardo; Fréderic Grenouillet; Isabel M Miranda; Raquel M Silva; Guilluame Eglin; Nadège Devillard; Acácio Gonçalves Rodrigues; Cidália Pina-Vaz
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

3.  Safety and tolerability of fluconazole in children.

Authors:  V Novelli; H Holzel
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

4.  Pharmacokinetic study of azithromycin with fluconazole and cotrimoxazole (trimethoprim-sulfamethoxazole) in healthy volunteers.

Authors:  G W Amsden; G Foulds; K Thakker
Journal:  Clin Drug Investig       Date:  2000       Impact factor: 2.859

5.  Comparative effects of antifungal agents on zidovudine glucuronidation by human liver microsomes.

Authors:  E Sampol; B Lacarelle; J F Rajaonarison; J Catalin; A Durand
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

6.  Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation.

Authors:  Verawan Uchaipichat; Leanne K Winner; Peter I Mackenzie; David J Elliot; J Andrew Williams; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

Review 7.  Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.

Authors:  Chris Stockmann; Jonathan E Constance; Jessica K Roberts; Jared Olson; Elizabeth H Doby; Krow Ampofo; Justin Stiers; Michael G Spigarelli; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 6.447

Review 8.  Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients.

Authors:  Kevin J Downes; Brian T Fisher; Nicole R Zane
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

9.  Pharmacokinetics of fluconazole in pediatric patients.

Authors:  K W Brammer; P E Coates
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-04       Impact factor: 3.267

Review 10.  The enzymatic basis of drug-drug interactions with systemic triazole antifungals.

Authors:  Yasmine Nivoix; Dominique Levêque; Raoul Herbrecht; Jean-Claude Koffel; Laurence Beretz; Genevieve Ubeaud-Sequier
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.